CClinicalTrials.gg
CompletedNCT01304264Updated Jan 12, 2012

Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients

An observational study in Open Angle Glaucoma, sponsored by Lithuanian University of Health Sciences. Completed at 1 site in Lithuania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-12.

Sponsored by Lithuanian University of Health Sciences · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate whether add-on to prostaglandin therapy with twice a day (bid) dorzolamide is statistically superior to twice a day (bid) timolol with regard to increasing ocular blood flow

Read the detailed description

Hypotensive treatments for glaucomatous optic neuropathy (GON), depending on their chemical composition can influence the ocular circulation independent of intraocular pressure (IOP) reduction. It is therefore important not only to identify ocular blood flow deficits in GON, but also document the influence of GON treatments on the ocular circulation

02

Conditions studied

  • Open Angle Glaucoma

Keywords

  • glaucoma, ocular, blood flow, fluctuations
03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's enrollment of 35 is below the median of 103 across 454 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Lithuanian University of Health Sciences is the lead sponsor of 102 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Regular visitors of Eye Clinic of Lithuania University of Health Science hospital

Inclusion criteria

  • Open angle glaucoma subjects receiving prostaglandin monotherapy in both eyes

Exclusion criteria

Exclusion Criteria:

  • younger than 18 years old
  • women of child bearing potential
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
35 participants (actual)

Groups and cohorts

  • combination topical glaucoma treatment

    timolol or dorzolamide add on latanoprost monotherapy

    Device: Color Doppler Imaging

Interventions

  • DeviceColor Doppler Imaging

    Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).

    Also known as: timololum maleate, dorzolamidum, latanoprostum

06

What researchers measure

Primary outcomes

  1. Ocular Color Doppler Imaging

    Color Doppler Imaging * Nasal post ciliary artery (NPCA) * Temporal posterior ciliary artery (TPCA) * Ophthalmic artery (OA) * Central retinal artery (CRA)

    Time frame: 8 AM; 8 PM

Secondary outcomes

  1. IOP, BP, OPP (mean, fluctuations, amplitude)

    IOP, BP, OPP (mean, fluctuations, amplitude) Goldmann applanation tonometry Brachial artery pressure and radial pulse

    Time frame: 8 AM-12AM-4PM-8PM

07

Study locations

1 site
  • Eye Clinic Lithuania Health Science Hospital Kaunas Clinics
    Kaunas, 50009, Lithuania
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01304264
Lead sponsor
Lithuanian University of Health Sciences
Collaborators
Indiana University School of Medicine, Merck Sharp & Dohme LLC
Responsible party
Ingrida Januleviciene (MD, Lithuanian University of Health Sciences) — Principal investigator
First posted
Feb 25, 2011
Start date
Mar 2011
Primary completion
Sep 2011
Completion
Nov 2011
Last update
Jan 12, 2012

Study contacts

Ingrida Januleviciene, MD
principal investigator · Lithuania University of Health Science

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion